Products
Fontolizumab Biosimilar Monoclonal Antibody (IFN-γ) for Research
Pre-Made Fontolizumab biosimilar, Whole mAb, Anti-IFNG Antibody: Anti-IFG/IFI/IMD69 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Fontolizumab (planned trade name HuZAF) is a humanized monoclonal antibody and an immunosuppressive drug for the treatment of auto-immune diseases like Crohn's disease. A phase II clinical trial investigating the use for rheumatoid arthritis was terminated because the first phase did not meet the endpoint.
Order Information
| Catalog No. | Package | List Price(In USD) | Discount off | Discount Price |
|---|---|---|---|---|
| GMP-Bios-ab-219-1mg | 1mg | 3090 |
Size： 1mg | 10mg | 100mg
Product Details
| Products Name (INN Index) | Pre-Made Fontolizumab biosimilar, Whole mAb, Anti-IFNG Antibody: Anti-IFG/IFI/IMD69 therapeutic antibody |
| INN Name | Fontolizumab |
| Target | IFNG |
| Format | Whole mAb |
| Derivation | Humanized |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-II |
| Est. Status | Discontinued |
| 100% SI Structure | None |
| 99% SI Structure | 1t3f:BA/1t04:DC:BA |
| 95-98% SI Structure | None |
| Year Proposed | 2002 |
| Year Recommended | 2003 |
| Companies | PDL BioPharma |
| Conditions Approved | na |
| Conditions Active | na |
| Conditions Discontinued | Autoimmune disorders;Crohn's disease;Psoriasis;Rheumatoid arthritis |
| Development Tech | na |
About target - IFNG
1. Protein Interferon gamma
2. Gene IFNG
3. Organism Homo sapiens (Human)
Function
Type II interferon produced by immune cells such as T-cells and NK cells that plays crucial roles in antimicrobial, antiviral, and antitumor responses by activating effector immune cells and enhancing antigen presentation (PubMed:16914093, PubMed:8666937).
Primarily signals through the JAK-STAT pathway after interaction with its receptor IFNGR1 to affect gene regulation (PubMed:8349687).
Upon IFNG binding, IFNGR1 intracellular domain opens out to allow association of downstream signaling components JAK2, JAK1 and STAT1, leading to STAT1 activation, nuclear translocation and transcription of IFNG-regulated genes. Many of the induced genes are transcription factors such as IRF1 that are able to further drive regulation of a next wave of transcription (PubMed:16914093).
Plays a role in class I antigen presentation pathway by inducing a replacement of catalytic proteasome subunits with immunoproteasome subunits (PubMed:8666937).
In turn, increases the quantity, quality, and repertoire of peptides for class I MHC loading (PubMed:8163024).
Increases the efficiency of peptide generation also by inducing the expression of activator PA28 that associates with the proteasome and alters its proteolytic cleavage preference (PubMed:11112687).
Up-regulates as well MHC II complexes on the cell surface by promoting expression of several key molecules such as cathepsins B/CTSB, H/CTSH, and L/CTSL (PubMed:7729559).
Participates in the regulation of hematopoietic stem cells during development and under homeostatic conditions by affecting their development, quiescence, and differentiation (By similarity).
